Simultaneous quantification of proposed anti-malarial combination comprising of lumefantrine and CDRI 97–78 in rat plasma using the HPLC–ESI-MS/MS method: application to drug interaction study

BACKGROUND: Lumefantrine is the mainstay of anti-malarial combination therapy in most endemic countries presently. However, it cannot be used alone owing to its long onset time of action. CDRI 97–78 is a promising trioxane-derivative anti-malarial candidate that is currently being investigated as a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wahajuddin, Muhammad, Singh, Sheelendra P, Taneja, Isha, Raju, Kanumuri SR, Gayen, Jiaur R, Siddiqui, Hefazat H, Singh, Shio K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429480/
https://www.ncbi.nlm.nih.gov/pubmed/25895956
http://dx.doi.org/10.1186/s12936-015-0684-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429480/
https://www.ncbi.nlm.nih.gov/pubmed/25895956
http://dx.doi.org/10.1186/s12936-015-0684-5

Ejemplares similares